My good friend from north of the border, Nancy Shamanna, asked me to share this link to a survey for patients that have taken daratumumab (Darzalex). She’s hoping a positive response might move Canadian officials to adopt the new immunotherapy sooner rather than later:
Myeloma Canada seeks patient and caregiver treatment input
Myeloma Canada invites myeloma patients who have used daratumumab and their caregivers to take a few minutes to complete a brief online survey by clicking on the link below.
The results of the survey will be included in a report to Health Canada as part of its drug approval process and to pCODR for its funding review (if the treatment receives approval from Health Canada).
Previously, we have conducted similar surveys for other treatments including bortezomib (Velcade®), pomalidomide (Pomalyst®) and lenalidomide (Revlimid®) (for maintenance treatment post-transplant and as first line treatment). Our input has been valued and positive funding decisions were made.
Your feedback is extremely important and, although there is no guarantee, may help to improve access to this drug for patients across Canada.
Please join us and have your say. This is a short survey; it should take less than 10 minutes. We ask that you complete the survey by Friday, January 15, 2016.
Francine Gendron, MBA, Adm.A.
Chief Executive Officer
As far as I know, its OK for U.S. patients to respond.
Glad to help our fellow myeloma patients up north anyway we can, Nancy. Good luck!
Feel good and keep smiling! Pat